• Contact
  • Press And News

Gut Health


Kluyveromyces B0399 and Intestinal microbiota in Covid-19 infected patients

Trial 252: Oral intake of Kluyveromyces marxianus B0399 plus Lactobacillus rhamnosus CECT 30579 to mitigate symptoms in COVID-19 patients: A randomized open label clinical trial Vicente Navarro-L&oac

Probiotic Lactic Yeast ® Kluyveromyces B0399: immune system stimulation, gut colonization, bifidobogenic effect and other strain specific, probiotic properties

Trial 143: Potential probiotic Kluyveromyces marxianus fragilis B0399 modulates the immune response in Caco-2 cells and PBMCs and impacts on the human gut microbiota in an in vitro colonic model syste

Gastric resistence and sattle in the intestine: Kluyveromyces B0399

Trial 138:Administration of a yogurt enriched with Kluyveromyces marxianus fragilis B0399 and Bifidobacterium l. BB12: a study on its impact on the intestinal microbiota of subjects with dysfunctional

Irritable Bowel Sindrome

Trial 132 Clinical results of treatment with the lactic yeast Kluyveromyces B0399 for Irritable Bowel Sindrome. This study, based on the gathering of symtomatological data before and after the treatme

Gastric resistance and colonization of the intestinal tract

Trial 130.1: The ability of Kluyveromyces marxianus fragilis B0399 to pass through the gastric barrier and colonize the intestine - examination of human feces after oral uptake by healthy volunteers.

Trial 125: Evaluation of the effects of a yogurt containing Kluyveromyces marxianus fragilis B0399 in patients suffering from Irritable Bowel Syndrome-a randomized, placebo controlled clinical study (abbreviated text)

This study evaluates the effects of a yogurt formulated with a new lactic yeast,Kluyveromyces marxianus fragilis B0399, in patients suffering from IBS. A double blind, monocentric study, controlled ag

Lactic yeast Kluyveromyces B0399 (Kluyver B0399) on patients suffering from irritable colon

Trial 16:The use of Saccaromyces cerevisiae and Kluyveromyces fragilis B0399 is recommended in all cases of intestinal dismicrobism induced by organic diseases and/or antibiotics, but also for putting

EXPERTISE: Improved lactose utilisation as a footprint of domestication in the K. marxianus B0399 “fragilis” lineage

Scientific expertise: "THE SCIENCE UNDERLYING TRADITIONAL HUMAN ACTIVITY FOR INDUSTRY EXPLOITATION OF KLUYVEROMYCES MARXIANUS – improved lactose utilisation as a footprint of domestication in th
2024. © All rights reserved. Laboratori Turval Italia srl (TURVAL Laboratories Ltd.) - Head Office and Research Dpt: Friuli innovazione (AREA international Science Park-TS), Via Linussio 51-33100 Udine (IT) – P. IVA 01883020305
We use cookies to enhance your browsing experience. If you want to disable cookies, please set your browser.